Skip Navigation

This Article
Right arrow FREE Full Text (Print PDF) Freely available
Right arrow FREE Full Text (Screen PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Patterson, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patterson, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Bioinformatics Vol. 18 no. 90002 2002
Pages S181
© 2002 Oxford University Press

Selecting targets for therapeutic validation through differential protein expression using chromatography-mass spectrometry

Scott Patterson 1

1 Celera, Rockville, USA

Received on April 8, 2002 ; accepted on June 15, 2002

The identification of potential targets for therapeutic intervention can be accomplished on a systematic basis by a variety of techniques that include quantitative analysis of gene-specific mRNA levels and expressed proteins in normal and diseased cells. Differences in the expression levels of nucleic acid and protein gene products could suggest protein drug targets that are directly causative of disease, or reveal biochemical pathways that could be modulated by therapeutic molecules. Any effort based on mRNA or protein expression level comparisons could be confounded by a number of factors:

level in steady-state may not be correlated with actual encoded protein levels;

differentially expressed protein levels might be a result of disease process, and not causative of the process, and therapeutic intervention based on such a difference will be unproductive and

the differential expression of mRNA or protein may be the result of biological variation unrelated to the disease process under study.

In order to address these possibly confounding factors, it is necessary to validate potential targets by establishing their firm association with disease, and their minimal distribution in non-diseased tissues of any type. This requirement suggests that emphasis on true and reproducible quantitation of protein expression levels in a variety of samples will be an effective and highly efficient method of generating drug targets with a high degree of utility. To achieve this aim, we have established an industrial-scale proteomics-based discovery platform consisting of cell biology, protein chemistry, and mass spectrometry technical groups together with bioinformatics groups. The analytical method used for quantitation employs isotope labeling for differential analysis (ICATTM, Applied Biosystems, Inc.). With this technique, tryptic peptides are generated from labeled proteins that have been specifically captured from various subcellular locations or protein families. The resulting peptides are identified and quantified by mass spectrometry. To evaluate this approach on a large-scale, we have applied it to a study of continuous cell lines derived from human pancreatic adenocarcinomas. We have been able to establish processes for target discovery for small molecule drug targets as well as therapeutic antibody target identification for cell surface proteins. In addition, we have developed a process for identification of serum markers of this disease based upon standardized fractionation procedures. The results of these analyses will be presented together with the some of the issues from both the wet and dry (computational) lab that need to be addressed in such an undertaking.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BioinformaticsHome page
K. Malde, E. Coward, and I. Jonassen
A graph based algorithm for generating EST consensus sequences
Bioinformatics, April 15, 2005; 21(8): 1371 - 1375.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
N. Kim, S. Shin, and S. Lee
ECgene: Genome-based EST clustering and gene modeling for alternative splicing
Genome Res., April 1, 2005; 15(4): 566 - 576.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
L. Florea, V. Di Francesco, J. Miller, R. Turner, A. Yao, M. Harris, B. Walenz, C. Mobarry, G. V. Merkulov, R. Charlab, et al.
Gene and alternative splicing annotation with AIR
Genome Res., January 1, 2005; 15(1): 54 - 66.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
B. Raphael, D. Zhi, H. Tang, and P. Pevzner
A novel method for multiple alignment of sequences with repeated and shuffled elements
Genome Res., November 1, 2004; 14(11): 2336 - 2346.
[Abstract] [Full Text] [PDF]


Home page
Genome ResHome page
P. A. Pevzner, H. Tang, and G. Tesler
De Novo Repeat Classification and Fragment Assembly
Genome Res., September 1, 2004; 14(9): 1786 - 1796.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Resch, Y. Xing, A. Alekseyenko, B. Modrek, and C. Lee
Evidence for a subpopulation of conserved alternative splicing events under selection pressure for protein reading frame preservation
Nucleic Acids Res., February 24, 2004; 32(4): 1261 - 1269.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.